|Baxter Presents Data on the Role of SHARESOURCE Telehealth Platform in Helping the Clinical Management of Peritoneal Dialysis Patients|
|View printer-friendly version|
SHARESOURCE, which has helped remotely manage more than 1 million PD therapy treatments globally, is a two-way, cloud-based technology platform that is featured in Baxter’s AMIA automated PD (APD) system and HOMECHOICE CLARIA APD system. SHARESOURCE allows healthcare providers to securely view their patients’ recently completed home dialysis-related treatment data that is automatically collected after each PD session. Healthcare providers can then act on this information by remotely adjusting their patients’ home device settings without requiring them to travel to the clinic.
“We are seeing growing evidence that reinforces the value remote patient
management provides dialysis providers and their PD patients,” said
Using SHARESOURCE for Early Suspicion of Peritonitis Episodes
Peritonitis is a condition usually brought on by infection and causes inflammation of the tissue that lines the inner wall of the abdomen. It is a well-known complication for PD patients and a leading cause of technique failure that can lead to therapy dropout.
Ultrafiltration (UF), a key target of dialysis treatment, is the amount of fluid volume removed from a patient. While patient ultrafiltration varies somewhat on a daily basis, there is usually some consistency in the UF seen from day to day for an individual patient.
In a retrospective study, “Help of Remote Patient Monitoring in the
Assessment of Changes in Ultrafiltration Before, During and After a
Peritonitis Episode in Patients on APD” (Abstract #TH-PO870), clinicians
at the Hospital Belisario Domínguez,
Analysis of the data showed significant differences in ultrafiltration depending on temporal proximity to the episode of peritonitis as follows:
“This is the first study to show how remote patient management data can
be used to detect changes in ultrafiltration, information which might be
used by physicians in the future as an early clue to trigger
investigation for peritonitis,” said
Using SHARESOURCE to Detect Late Catheter Dysfunction
Despite significant advancements in the management of PD, catheter dysfunction remains a major cause of therapy dropout, with some studies estimating that it accounts for 20 percent to 25 percent of permanent transition to hemodialysis. “Late” catheter dysfunction, defined here as occurring at least one month after therapy begins, can be caused by leaks, perforation, obstruction or infection.
In a study, “Pattern of Late Catheter Dysfunction in APD Patients
Detected through Remote Patient Monitoring and its Impact in Therapy
Total Time” (Abstract #PUB347), clinicians at Hospital Belisario
The clinicians, along with Baxter researchers, used SHARESOURCE data to compare these four patients with 10 randomly selected patients who did not show abnormal drainage. The team looked at total therapy time (median time in minutes per therapy session), median catheter drainage time, median catheter infusion time, and ultrafiltration. The results are included in the table below; no differences were found in blood pressure levels or occurrence of edema between the groups.
The assessment demonstrated patients with catheter dysfunction had increased drainage time and lost effective therapy time. Clinicians also found a correlation between lost therapy time and lower ultrafiltration.
Early identification of abnormal PD catheter flow patterns using SHARESOURCE can inform clinicians about the need to mitigate problems that can lead to suboptimal dialysis outcomes.
AMIA with SHARESOURCE is available in
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Rx Only. For safe and proper use of the devices mentioned herein, refer to the complete instructions in the Operator's Manual.
This release includes forward-looking statements concerning AMIA,
HOMECHOICE CLARIA and SHARESOURCE remote patient management platform,
including potential benefits associated with their use (including the
potential earlier detection of peritonitis). The statements are based on
assumptions about many important factors, including the following, which
could cause actual results to differ materially from those in the
forward-looking statements: satisfaction of regulatory and other
requirements; actions of regulatory bodies and other governmental
authorities; product quality, manufacturing or supply, or patient safety
issues; changes in law and regulations; and other risks identified in
Baxter's most recent filing on Form 10-K and other
Baxter, SHARESOURCE, AMIA and HOMECHOICE CLARIA are registered
Baxter International Inc.